Skip to main content
SpringerLink
Log in
Book cover

Antibiotic Discovery and Development

  • Book
  • © 2012

Overview

Editors:
  1. Thomas J. Dougherty

    1. , Senior Principal Scientist, AstraZeneca Pharmaceuticals LP, Waltham, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Michael J. Pucci

    1. Achillion Pharmaceuticals, Inc., New Haven, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Chapters written by experts in their fields

  • Contains helpful, full-color illustrations

  • Features up-to-date research

  • Includes supplementary material: sn.pub/extras

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (37 chapters)

  1. Front Matter

    Pages i-xvii
    Download chapter PDF

  2. Introductory History of Antimicrobial Drugs

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. The Early History of Antibiotic Discovery: Empiricism Ruled

      • Richard J. White
      Pages 3-31

    3. Rational Approaches to Antibacterial Discovery: Pre-Genomic Directed and Phenotypic Screening

      • Lynn L. Silver
      Pages 33-75

  3. Marketed Major Classes of Compounds

    1. Front Matter

      Pages 77-77
      Download chapter PDF

    2. Beta-Lactam Antibiotics

      • Malcolm G. P. Page
      Pages 79-117

    3. Review of the Quinolone Family

      • George A. Jacoby, David C. Hooper
      Pages 119-146

    4. Tetracyclines

      • Patricia A. Bradford, C. Hal Jones
      Pages 147-179

    5. Macrolides and Ketolides

      • Ze-Qi Xu, Michael T. Flavin, David A. Eiznhamer
      Pages 181-228

    6. Aminoglycosides

      • Eliana S. Armstrong, Corwin F. Kostrub, Robert T. Cass, Heinz E. Moser, Alisa W. Serio, George H. Miller
      Pages 229-269

    7. Oxazolidinone Antibacterial Agents

      • Michael R. Barbachyn
      Pages 271-299

    8. Glycopeptides and Lipoglycopeptides

      • F. F. Arhin, A. Belley, A. Rafai Far, D. Lehoux, G. Moeck, T. R. Parr Jr.
      Pages 301-346

  4. The Rise of Antibiotic Resistance/Resistance Mechanisms to Major Classes

    1. Front Matter

      Pages 347-347
      Download chapter PDF

    2. Efflux-Mediated Antimicrobial Resistance

      • Keith Poole
      Pages 349-395

    3. Structural Mechanisms of β-Lactam Antibiotic Resistance in Penicillin-Binding Proteins

      • Robert A. Nicholas, Christopher Davies
      Pages 397-425

    4. Evolution of β-Lactamases: Past, Present, and Future

      • Karen Bush
      Pages 427-453

    5. Inducible Resistance to Macrolide Antibiotics

      • Sai Lakshmi Subramanian, Haripriya Ramu, Alexander S. Mankin
      Pages 455-484

    6. Fluoroquinolone Resistance: Mechanisms, Restrictive Dosing, and Anti-Mutant Screening Strategies for New Compounds

      • Karl Drlica, Xilin Zhao, Muhammad Malik, Tal Salz, Robert Kerns
      Pages 485-514

    7. Glycopeptide Resistance

      • Bruno Périchon, Patrice Courvalin
      Pages 515-542

    8. Acquired Tetracycline Resistance Genes

      • Marilyn C. Roberts
      Pages 543-568
Back to top

About this book

This volume covers all aspects of the antibiotic discovery and development process through Phase II/III. The contributors, a group of highly experienced individuals in both academics and industry, include chapters on the need for new antibiotic compounds, strategies for screening for new antibiotics, sources of novel synthetic and natural antibiotics, discovery phases of lead development and optimization, and candidate compound nominations into development. Beyond discovery , the handbook will cover all of the studies to prepare for IND submission: Phase I (safety and dose ranging), progression to Phase II (efficacy), and Phase III (capturing desired initial indications). This book walks the reader through all aspects of the process, which has never been done before in a single reference. With the rise of antibiotic resistance and the increasing view that a crisis may be looming in infectious diseases, there are strong signs of renewed emphasis in antibiotic research. The purpose of the handbook is to offer a detailed overview of all aspects of the problem posed by antibiotic discovery and development.

Editors and Affiliations

  • , Senior Principal Scientist, AstraZeneca Pharmaceuticals LP, Waltham, USA

    Thomas J. Dougherty

  • Achillion Pharmaceuticals, Inc., New Haven, USA

    Michael J. Pucci

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation